Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy. (3rd September 2019)

• Record Type: Journal Article
• Authors: Orellana, Laura
• Is Part Of: Molecular & cellular oncology. Volume 6:Number 5(2019)
• Publication Date: 2019-09-03
• Subjects: EGFR -- ectomutations -- convergence -- mAb806 -- kinase inhibitors; Tumors -- Periodicals; Neoplasms; Periodicals; 616.99
• DOI: 10.1080/23723556.2019.1630798
• Languages: English
• ISSNs: 2372-3556

Abstract

ABSTRACT: EGFR mutations display striking organ-site asymmetry and heterogeneity. We have shown that structurally diverse extracellular mutations, typical of glioblastomas, converge to a similar intermediate conformation, which can be synergistically targeted extra- and intracelullarly by antibody mAb806 and type-II kinase inhibitors. Our findings reveal convergence behind heterogeneity, paving the way for allostery-based co-targeting.